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TNF-a Suppresses a-Smooth Muscle Actin Expression
in Human Dermal Fibroblasts: An Implication for
Abnormal Wound Healing
Mytien T. Goldberg1, Yuan-Ping Han1, Chunli Yan1, Michael C. Shaw2 and Warren L. Garner1
Abnormal wound healing encompasses a wide spectrum, from chronic wounds to hypertrophic scars. Both
conditions are associated with an abnormal cytokine profile in the wound bed. In this study, we sought to
understand the dynamic relationships between myofibroblast differentiation and mechanical performance of
the collagen matrix under tissue growth factor–b (TGF-b) and tumor necrosis factor–a (TNF-a) stimulation. We
found TGF-b increased a-smooth muscle actin (a-SMA) and TNF-a alone decreased the basal a-SMA expression.
When TGF-b1 and TNF-a were both added, the a-SMA expression was suppressed below the baseline. Real-time
PCR showed that TNF-a suppresses TGF-b1-induced myofibroblast (fibroproliferative) phenotypic genes, for
example, a-SMA, collagen type 1A, and fibronectin at the mRNA level. TNF-a suppresses TGF-b1-induced gene
expression by affecting its mRNA stability. Our results further showed that TNF-a inhibits TGF-b1-induced Smad-
3 phosphorylation via Jun N-terminal kinase signaling. Mechanical testing showed that TNF-a decreases the
stiffness and contraction of the lattices after 5 days in culture. We proposed that changes in a-SMA, collagen,
and fibronectin expression result in decreased contraction and stiffness of collagen matrices. Therefore, the
balance of cytokines in a wound defines the mechanical properties of the extracellular matrix and optimal
wound healing.
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INTRODUCTION
Myofibroblasts are a specialized subgroup of cells with features
of both fibroblasts and smooth muscle cells. The most significant
marker for myofibroblasts is the expression of a-smooth muscle
actin (a-SMA) within cytoplasmic stress fibers. However,
myofibroblasts also show increased production of collagens I,
III, V, fibronectin, and proteoglycan (Serini and Gabbiani,
1999), proteins that characterize fibrotic disease. It has been
widely believed that the myofibroblast’s ability to generate
contractile forces is due to the accumulation of cytoplasmic
actins and cellular fibronectin, resulting in reorganization of the
extracellular matrix (ECM) (Tomasek et al., 2002).
Tissue growth factor–b1 (TGF-b1) is a key cytokine in
normal wound healing and fibrosis (Roberts et al., 2003). It is
known to induce a-SMA expression in fibroblasts both in vitro
and in vivo (Desmouliere et al., 1993; Roy et al., 2001). TGF-b1
also stimulates ECM synthesis, especially collagen I, and
inhibits the activity of matrix metalloproteinases by decreas-
ing their expression and upregulating tissue inhibitor of
metalloproteinase expression (Gabbiani, 2003). Therefore, it
controls two important activities of granulation tissue: tissue
contraction and ECM remodeling.
The TGF-b family exerts its effects mainly through Smad
signal transduction pathways (Zhang and Laiho, 2003). The
signal transduction starts with ligand-binding activation of
the receptor complex, followed by phosphorylation of the
receptor-activated Smad2 and -3 by the type I receptor. The
phosphorylated R-Smads then associate with Smad4 and
migrate into the nucleus, where they modulate the transcrip-
tion of a large number of genes. The Smad signaling pathway
is implicated in TGF-b1 induction of a-SMA expression and
formation of actin-stress fibers (Edlund et al., 2002, 2004;
Evans et al., 2003).
Tumor necrosis factor–a (TNF-a) is a potent inflammatory
cytokine expressed during the inflammatory phase of wound
healing. TNF-a, secreted by inflammatory cells, both inhibits
ECM synthesis and activates matrix metalloproteinases
(Singer and Clark, 1999). Recent studies have demonstrated
that inflammatory cytokines have antagonistic activities
against TGF-b1 (Mauviel et al., 1993; Abraham et al.,
2000). For example, TNF-a antagonizes TGF-b1-induced
upregulation of type I and III collagens in fibroblasts through
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a Jun N-terminal kinase (JNK)-dependent regulatory mechan-
ism in mouse fibroblasts (Verrecchia et al., 2003). Mariani
et al. (1999) showed that TNF-a suppresses both tropoelastin
and a-SMA expression in rat lung fibroblasts. The antagonist
relationship between TGF-b1 and TNF-a may play an
important role in maintaining tissue homeostasis and ECM
deposition.
The increased level of a-SMA found in myofibroblast is
potentially important for the contractile features of these cells
under normal tissue repair and fibrotic conditions. Fibroblasts
embedded in collagen matrix under mechanical stress have
been shown to exert mechanical force on the collagen lattice,
leading to reorganization of the matrix and alignment of the
cells along the principal strain of the lattice (Delvoye et al.,
1991; Kolodney and Wysolmerski, 1992; Eastwood et al.,
1994). However, few studies have attempted to measure the
mechanical properties of collagen lattice after matrix
reorganization. Therefore, an increased knowledge of the
induction and suppression of a-SMA expression correlating
with the mechanical properties of the ECM would be of
interest. On the basis of several findings of antagonistic
activity of TNF-a on TGF-b1 activity, we sought to ascertain
(i) the antagonistic activity of TNF-a on TGF-b1 induction of
a-SMA expression, (ii) the role of the mitogenic-activated
protein kinase (MAPK) signaling in TNF-a suppression of
TGF-b1-induced a-SMA expression, (iii) whether TNF-a
antagonistic activity on TGF-b1 is through inhibition of
Smad3 phosphorylation, and (iv) the correlation between
mechanical and molecular response of fibroblasts in collagen
matrix to TGF-b1 and TNF-a actions by measuring the rate of
lattice contraction and the stiffness of the collagen lattice. We
examined the above objectives in human fibroblasts em-
bedded in collagen 1 matrix, which remained attached to the
substratum of the culture plate, also known as stressed
fibroblast-populated collagen matrix.
RESULTS
TGF-b1 induces a-SMA expression and TNF-a suppresses its
induction in human dermal fibroblasts
Desmouliere et al. (1992) have shown that TGF-b1 induces
a-SMA expression in both quiescent and growing human
dermal fibroblasts in monolayer. By contrast, TNF-a is known
to have no effect on a-SMA expression in granulation tissue.
However, TNF-amediates antagonistic activity against TGF-b1
in synthesis of collagen types I and III. Therefore, we
examined whether TNF-a exhibits the same antagonistic
activity against TGF-b1-induced upregulation of a-SMA. To
simulate the microenvironment of dermis, isolated human
dermal fibroblasts at early passages were embedded in three-
dimensional type-I collagen matrices attached to the culture
plate designated for stressed fibroblast-populated collagen
lattices (FPCLs). To recapitulate the wound environment or
scar formation, stressed FPCLs were treated with TGF-b1. In
the absence of TGF-b1 treatment, the stressed FPCLs showed
minimal expression of a-SMA. As expected, TGF-b1 sig-
nificantly increased a-SMA expression above that of the non-
stimulated fibroblasts, consistent with previous published
works (Figure 1). In contrast to previous reports of TNF-a
having no effect on a-SMA expression in fibroblasts in a
mouse wound model (Desmouliere et al., 1992), here we
showed that TNF-a alone suppressed a-SMA below the
baseline in human dermal fibroblasts. Interestingly, during
treatment with both TGF-b1 (1 ng/ml) and TNF-a (up to 2 ng/
ml), TNF-a reversed the ability of TGF-b1 to upregulate a-
SMA. We also examined the expression of vimentin protein, a
member of the intermediate filament family, under the same
experimental conditions and did not see any effects
attributable to TGF-b1 or TNF-a. The vimentin protein acted
as an internal control along with glyceraldehydes-3-phos-
phate dehydrogenase (GAPDH) protein.
We next undertook to determine whether TNF-a could
suppress TGF-b1-promoted formation of the stress fibers that
characterize myofibroblasts. Stressed FPCLs were cultured in
the presence or absence of 1 ng/ml TGF-b1 or TGF-b1
combined with TNF-a (1 ng/ml each) for 5 days, followed by
fixation. The lattices were immunostained for a-SMA (Figure
2a and b). The immunofluorescence, using monoclonal
antibody–recognizing human a-SMA, showed that TGF-b1
increased stress fibers containing a-SMA compared with the
control group. However, when we combined TGF-b1 with
TNF-a, the expression of actin stress fibers was suppressed
back to the basal levels. Furthermore, TGF-b1-treated lattices
had significantly larger stress fibers compared with lattices
treated with TGF-b1 and TNF-a. We also examined the actin
cytoskeleton and morphology of fibroblasts in stress FPCL
under the stimulation of the same cytokines by staining with
rhodamine-conjugated phalloidin, a florescence probe that
binds F-actin (Figure 2e–h). Under resting condition of 0.1%
fetal bovine serum (FBS), stressed FPCL demonstrated F-actin
stress fibers as expected. The mechanical stress within the
FPCL-induced stress fibers has been shown in granulation
tissue (Tomasek et al., 2002). Following stimulation with
TGF-b1 (1 ng/ml), fibroblasts within stressed FPCL became
larger and polygonal compared with unstimulated control
cells. Furthermore, the cells demonstrated larger actin fibers
with increasing thickness and the number of stress fibers. For
stressed FPCLs treated with TNF-a (10 ng/ml) and TNF-a
(10 ng/ml) plus TGF-b1 (1 ng/ml), cells had a small spindle-
shaped appearance and no significant stress F-actin fibers.
These findings provide further support for the hypothesis that
TGF-1(1 ng/ml)
TGF-1(ng/ml)
-SMA
Vimentin
– + – + + + –
– – 1 0.1 0.5 1 2
GAPDH
Figure 1. TNF-a suppresses TGF-b1 induction in human dermal fibroblasts.
Normal human dermal fibroblasts (3 105 cells/ml) were seeded in collagen I
matrix (1 mg/ml). The fibroblast-populated collagen lattices (FPCLs) were
treated with TGF-b1 (1 ng/ml), TNF-a (1 ng/ml), or combinations of TGF-b1
(1 ng/ml) and increasing concentrations of TNF-a for 96 hours under 0.1%
serum conditions. Representative Western blots for a-SMA, vimentin, and
GAPDH are shown.
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TNF-a can suppress TGF-b1 promotion of stress fibers and
cytoskeletal changes essential for myofibroblasts differentia-
tion.
During skin wound repair, fibroblasts go through a
transition from fibroblast to myofibroblast under the influ-
ences of mechanical stress, cytokines, and an array of ECM
molecules. The transition between fibroblasts and myofibro-
blasts results in fibroblast–ECM matrix remodeling and thus
leads to a change in the matrix mechanical tension. Few
studies have attempted to measure directly this mechanical
tension within the ECM of a healing wound. For this, we used
an indentation assay to measure the stiffness of the collagen
matrix under different cytokine stimulations. In Figure 3,
stressed fibroblast collagen lattices were constructed and
induced with TGF-b1, TNF-a, or a combination of TGF-b1
and TNF-a for 4 days. The lattices were then tested and the
Young’s modulus (representative of the mechanical stiffness
of the collagen matrix) was determined. The results showed
that TGF-b1 stimulation caused an insignificant increase in
the stiffness (Young’s modulus of 2,0107280 Pa) compared
with the control with P¼ 0.16 (Young’s modulus of
1,7407185 Pa). However, TNF-a treatment alone or com-
bined with TGF-b1 resulted in a significantly decreased
stiffness of the matrices with P¼0.01 (Young’s modulus of
1,260 and 1,300780 Pa, respectively).
TNF-a suppresses TGF-b1-induced gene expression at the
mRNA level
The next question is whether TNF-a suppression of TGF-b1-
induced upregulation of a-SMA, collagen type I, and
fibronectin occurred at the mRNA level (Figure 4). In these
experiments, we used quantitative real-time reverse tran-
scriptase-PCR to determine the levels of expression of a-SMA,
fibronectin, and collagen 1A. We normalized the quantified
mRNA of each gene to its GAPDH mRNA and the results
show an increase in folds. We showed that TGF-b1 induced
increases in collagen type I, fibronectin, and a-SMA mRNA
levels after 24 hours of cytokine treatments and declined by
48 hours (Figure 4a). However, when fibroblasts were treated
with TNF-a plus TGF-b1, the mRNA levels of all three genes
were suppressed. In Figure 4b, TGF-b1-treated matrices had
an eightfold increase in mRNA expression compared to only
a twofold increase in the matrices treated with TGF b1
combined with TNF-a (Po0.001). Fibronectin mRNA
showed an 18-fold increase at 24 hours in TGF-b1 treatment
a c e g
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Figure 2. TNF-a suppresses TGF-b1 promotion of myofibroblast structural elements. (a–d) Representative images of the immunohistochemistry staining for
a-SMA. Normal human dermal fibroblasts (1105 cells) were seeded in collagen I matrix (1 mg/ml), which remained attach to the culture plate throughout
the cytokine stimulation period. a-SMA was visualized using mouse monoclonal a-SMA FITC conjugated. (a) FPCL under control conditions at 96 hours.
(b) FPCL treated with TGF-b1 (1 ng/ml) for 96 hours. (c) FPCL treated with TNF-a (1 ng/ml), and (d) FPCL treated with combination of TGF-b1 (1 ng/ml) and
TNF-a (1 ng/ml). Bars¼ 50 mm (panels a–d). (e–h) Rhodamine-conjugated phalloidin staining for F-actin to examine the assembly of stress fibers. (e) FPCL
under control conditions at 96 hours. (f) FPCL treated with TGF-b1 (1 ng/ml) for 96 hours. (g) FPCL treated with TNF-a (1 ng/ml), and (h) FPCL treated with a
combination of TGF-b1 (1 ng/ml) plus TNF-a (1 ng/ml). Bars¼ 50 mm (panels e–h).
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Figure 3. TNF-a affects the mechanical response of the fibroblast collagen
constructs. The mechanical response of FPCL treated with TGF-b1 (1 ng/ml),
TNF-a (1 ng/ml), and a combination of TGF-b1 and TNF-a were measured
using compressive indentation assay. In the indentation assay, normal
fibroblasts (3 105 cells/cm3) were seeded in collagen I matrix (1.5 mg/ml)
and induced with cytokines for 72 hours. The constructs underwent
indentation measurements. (a) Schematic of the mechanical test and equation
used for calculating Young’s modulus. (b) The data are expressed as Young’s
modulus for each experimental group.
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compared with only a threefold increase when TNF-a was
combined with TGF-b1 (Po0.01; Figure 4c). The same trend
was observed with collagen type 1A mRNA. At 24 hours,
collagen 1A mRNA increased sixfold with the TGF-b1
treatment groups, and decreased to 1.5-fold in the groups
treated with TGF-b1 plus TNF-a (P¼0.01; Figure 4d). These
results demonstrate consistent suppression by TNF-a of TGF-
b1-induced myofibroblast phenotypic genes, at the mRNA
level.
TNF-a suppresses TGF-b1-induced gene expression by affecting
mRNA stability
To elucidate possible post-transcriptional mechanisms that
could explain TNF-a negative effects on a-SMA mRNA levels
seen in our quantitative reverse transcriptase-PCR experi-
ments, we measured a-SMA mRNA stability (Figure 5). Earlier
studies showed that TGF-b1 stabilizes collagen I, fibronectin,
and thrombospondin mRNA in mouse 3T3 cells, with
maximal increase at 16–24 hours after induction (Penttinen
et al., 1988). However, the effect of TGF-b1 and TNF-a on
a-SMA mRNA stability has not previously been examined. In
these experiments, human dermal fibroblasts were stimulated
with TGF-b1 or TGF-b1 combined with TNF-a for 24 hours.
At the end of 24-hour cytokine induction, actinomycin D
(2.5 mg/ml) was added to the media and total RNA was
harvested at 0, 2, 4, 6, 8, and 24 hours. Real-time quantitative
reverse transcriptase-PCR was used to measure a-SMA mRNA
levels. The results showed that TGF-b1 stabilized a-SMA
mRNA levels with t1/2 of 53 hours. Interestingly, TNF-a
destabilized a-SMA transcripts 10-fold, with t1/2 of only
5 hours. The result suggests that TNF-a can abrogate
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Figure 4. TNF-a suppresses TGF-b1-induced gene expression at the mRNA level. Fibroblast-populated collagen lattice (FPCL) was prepared at a final cell
density of 1.5106 cells/ml in collagen (1 mg/ml) and a 4 ml gel cell mixture was plated in 6 cm2 plate. After polymerization, the FPCL was induced with
TGF-b1 (1 ng/ml), TNF-a (1 ng/ml), and TGF-b1 (1 ng/ml) plus TNF-a (1 ng/ml) in DMEM containing 0.1% FBS. Total RNA was extracted and reverse-transcribed
into cDNA. cDNA was analyzed for the mRNA expression of a SMA, fibronectin, collagen 1A, and GAPDH by real-time PCR. Results were expressed as a
ratio of target gene to GAPDH. Results from three independent experiments are shown with means7SE (a) Results for TGF-b1 induction of a-SMA,
fibronectin, and collagen 1A. (b–d) TNF-a suppression of a SMA, fibronectin, and collagen 1A, respectively.
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Figure 5. TNF-a affects a-SMA mRNA stability. Adult human dermal
fibroblasts were grown in monolayer to confluence and serum-starved for
16 hours before induction with TGF-b1 (1 ng/ml) or TGF-b1 (1 ng/ml) plus
TNF-a (1 ng/ml) for 24 hours. At the end of 24 hours, actinomycin D (2.5 mg/
ml) was added and total RNA was harvested at different time points for real-
time PCR analysis. The graph represents a ratio of a-SMA and GAPDH mRNA
versus time from three independent experiments with SD.
2648 Journal of Investigative Dermatology (2007), Volume 127
MT Goldberg et al.
TNF-a Suppresses Myofibroblast Differentiation
TGF-b-induced a-SMA production through destabilization of
its mRNA.
TNF-a decreases the contraction of FPCLs
We also examined the correlation between TNF-a suppres-
sion of a-SMA expression and the contractile force within the
collagen lattice (Figure 6). We used the attached and delayed
released contraction model, which has been shown to
represent the actual contraction force exerted by fibroblasts
(Tomasek et al., 1992). The FPCL was cast in high-density –
500,000 fibroblasts per milliliter – lattice, which remained
attached throughout the cytokine stimulation period. After 4
days of cytokine stimulation, the stressed FPCL was mechani-
cally released from the culture well. It contracted rapidly
within 60 minutes, and the percent gel contraction was
calculated as area of gel at the end of contraction divided by
area of gel before release from the culture plate. Serum-
starved treatments (0.1% FBS) showed considerably less
contraction than fully stimulated treatments (5% FBS); 55 vs
25% gel contraction, respectively. TGF-b1 (1 ng/mlþ 0.1%
FBS)-treated FPCL showed significant contraction compared
with the serum-starved controls; 25 vs 55%. FPCL treated
with TNF-a (10 ng/ml in 0.1% FBS) alone showed minimal
contraction equivalent to the untreated controls; 64 vs 55%.
However, treatment of FPCL with TGF-b1 combined with
TNF-a showed minimal contraction compared with treat-
ments with TGF-b1 alone; 55 vs 25%. We observed similar
results using a free-floating gel contraction assay model (data
not shown). Thus, TNF-a abolished TGF-b1-induced myofi-
broblast contractility.
Differential participation of protein kinase (MAPK) cascades in
TNF-a antagonistic effect on TGF-b1 induction of a-SMA
expression
Activation of TNF receptors leads to recruitment of tumor
necrosis factor receptor–associated factor family members,
and leads to activation of multiple signal transduction
pathways such as NF-kB, JNK, p38 MAP, and phosphoinosi-
tide 3-kinase. To gain insight into the cellular mechanisms by
which TNF-a suppresses TGF-b1-induced a-SMA expression,
we focused on the functions of two major downstream MAPK
cascades, p38 MAPK and JNK.
First, we tested whether TNF-a treatment would activate
the JNK pathway. As shown in Figure 7a, TNF-a treatment
leads to phosphorylation of JNK at Thr 183 and Tyr 185, using
mouse monoclonal antibody in human dermal fibroblasts in
stressed FPCL. This indicates that intracellular JNK activation
is present in primary adult human fibroblast cells in response
to TNF-a.
Utilizing chemical inhibitors for p38 MAPK and JNK, we
examined the effect of TNF-a on these signaling pathways
and their possible association with suppression of a-SMA
expression. The cells were grown in stressed collagen I matrix
and induced with TGF-b1 (1 ng/ml), TNF-a (1 ng/ml), and
TGF-b1 (1 ng/ml) together with TNF-a (1 ng/ml). The chemi-
cal inhibitors were added at the same time as the cytokines.
After 5 days of treatment, the cells were harvested and
Western blots were used to examine a-SMA. As shown in
Figure 7b and c, blockade of the p38 MAPK pathway by
highly specific chemical inhibitor SB202190 (4 mM) did not
affect TNF-a suppression of TGF-b1-induced a-SMA expres-
sion compared with the untreated group. SB202190 also had
no effect on TGF-b1 upregulation of a-SMA expression.
However, blockade of JNK pathway by SP600125 (30 mM)
resulted in reversal of TNF-a suppression. The cells treated
with SP600125 showed no suppression effect by TNF-a.
These results suggest that the JNK pathway plays a central
role in mediating TNF-a suppression of a-SMA expression.
TNF-a inhibits Smad3 phosphorylation in normal human dermal
fibroblasts
Smad signaling is considered the principal signaling pathway
for TGF-b. Smads affect the transcription of specific genes
through direct or indirect binding to their promoters. As
previous studies have demonstrated specific interaction
between the MAPK cascade and TGF-b-driven Smad signaling
(Verrecchia et al., 2003), we wanted to determine if TNF-a
inhibits phosphorylation of Smad3. Adult human dermal
fibroblasts were grown in monolayer to confluence and
serum starved for 16 hours before cytokine induction. Cells
0.1% FBS 5% FBS TNF- 1 ng/ml TGF- 1 ng/ml TGF-1+TNF-
0.1% FBS 0.1% FBS 0.1% FBS
Figure 6. TNF-a abolishes TGF-b1-induced myofibroblast contractility. The stressed fibroblast-populated collagen lattice (FPCL) was prepared in a final
cell density of 500,000 cells/ml plus collagen concentration of (1.5 mg/ml) and 0.6 ml volume per gel. The stressed FPCLs were treated under different
conditions for 4 days. At the end of treatment, the stressed FPCLs were mechanically released from culture plate and allowed to contract rapidly within
1 hour. The pictures were taken at the end of contraction.
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were then induced with TGF-b1 (1 ng/ml) alone or with a
combination of TGF-b1 (1 ng/ml) and TNF-a (1 ng/ml). As
shown in Figure 8, TGF-b1 activated Smad-3 phosphorylation
after 30 minutes of induction. In contrast, TNF-a inhibited
phosphorylation of Smad3 by TGF-b1. Therefore, it is likely
that TNF-a suppresses TGF-b1-induced a-SMA expression by
inhibiting Smad-3 phosphorylation via a JNK-dependent
pathway (Figure 9).
DISCUSSION
Cellular phenotypic changes within the wound environment
play an essential role in response to injury. The best studied
example of this is the transformation of fibroblasts into
myofibroblasts, which are present in both normal and fibrotic
wound healing. The key feature of these activated fibroblasts
or myofibroblasts is the expression of a-SMA (Darby et al.,
1990). The transition from fibroblast to myofibroblast also
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Figure 7. TNF-a decreases TGF-b1 induction of a-SMA expression in a JNK-dependent pathway. (a) Human dermal fibroblasts were grown in monolayer to
confluence and serum starved overnight followed by induction with TNF-a. Total protein was harvested at indicated time and Western blot analysis was
performed for phosphorylated JNK and JNK proteins. (b) FPCL was prepared in a final cell density of 300,000 cells/ml plus collagen concentration of 1 mg/ml and
induced with different cytokine combinations with or without SB202190 and SP600125 inhibitors for 96 hours. Cell lysates were analyzed for a-SMA and
GAPDH expression using Western blot. (c) The graph represents mean a-SMA expression as a ratio of GAPDH obtained by densitometric analysis from three
independent experiments.
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Figure 8. TNF-a inhibits Smad3 phosphorylation in normal human dermal
fibroblasts. To test whether TNF-a affects the TGF-b1 Smad signaling
pathway, human dermal fibroblasts were grown in monolayer and induced
with TGF-b1 (1 ng/ml) or TGF-b1(1 ng/ml) combined with TNF-a (1 ng/ml).
Cell lysates were analyzed for phosphorylated Smad3 and GAPDH using
Western blot analysis.
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involves the acquisition of stress fibers composed of
cytoplasmic actins and fibronectin under the influences of
both cytokines and mechanical stress within the wound
(Gabbiani, 2003).
Previous investigators have described TGF-b1 induction of
myofibroblast differentiation in both in vitro and in vivo
wound healing models (Ronnov-Jessen and Petersen, 1993;
Hinz et al., 2001). As we confirmed in our study, TGF-b1 is
an inducer of a-SMA expression and myofibroblast pheno-
type. Further, we showed that TGF-b1 stimulates a-SMA
expression at the mRNA level through stabilization of a-SMA
mRNA stability with t1/2 of 56 hours. Previous investigators
have only examined the effects of TNF-a on a-SMA
expression using an in vivo murine model (Rubbia-Brandt
et al., 1991; Desmouliere et al., 1992). In those studies, TNF-
a was locally infused into mouse wounds and the local
granulation tissues showed limited a-SMA expression com-
pared to other cytokines, that is, TGF-b, GM-CSF, and
heparin. From those experiments, the authors concluded that
TNF-a had no effect on a-SMA expression. In this study, we
used a more defined model and found that the situation is far
more complex and interesting. Treatment of human dermal
fibroblasts in a stressed three-dimensional collagen matrix
with TNF-a suppresses a-SMA expression below the unsti-
mulated controls. Of much greater interest, we documented
that TNF-a exposure abrogates TGF-b1 induction of a-SMA
expression at the post-transcriptional level by destabilizing a-
SMA mRNA. This response is not limited to this particular
protein. We are the first to report that TNF-a suppresses TGF-
b1-promoted increases of two other structural proteins,
collagen 1A and fibronectin. It is of interest that mRNA
levels for a-SMA, collagen I, and fibronectin declined after
48 hours, despite the continued presence of TGF-b1. Whether
this resulted from downregulation of TGF-b receptors or other
intracellular mechanisms served to blunt TGF-b1-induced
increases in mRNA levels is not yet known.
There is increasing evidence that suggests that members of
the stress-activated kinase pathways, JNK and P38 MAPK, are
involved in the interaction between these two cytokines. As
described above, they appear to mediate TNF-a antagonistic
activity against TGF-b1-induced a-SMA expression. The JNK
pathway has been shown to be involved in TNF-a antag-
onistic activity against TGF-b1-driven Smad3 and -4 col-
lagen1A1 and collagen 3A1 gene expression (Verrecchia
et al., 2003). Another study showed that treatment of human
prostate carcinoma cells with a MAPK p38 inhibitor resulted
in inhibition of TGF-b1-induced actin reorganization (Edlund
et al., 2002). These reports helped to trigger our interest in the
interaction of the signaling pathways during cytokine-
induced myofibroblast differentiation. To investigate these
phenomena, we utilized two pharmacological inhibitors. Our
results showed that an inhibitor of p38 MAPK (SB203580) did
not affect TNF-a suppression of TGF-b1-induced a-SMA
expression. By contrast, an inhibitor of JNK (SP600125)
reversed the suppression effect of TNF-a on TGF-b1-induced
a-SMA expression. The results suggest that the JNK pathway
plays a central role in mediating TNF-a suppression of a-SMA
expression.
Because Smad signaling plays a key role in transmitting
TGF-b1 signals, we investigated the effect of TNF-a on Smad3
phosphorylation. The results clearly showed that TNF-a
inhibits phosphorylation of Smad3. There is no consensus
in the literature on which members of the Smad family are
responsible for TGF-b1-induced a-SMA expression. One
study found that overexpression of Smad2, but not Smad3,
was responsible for upregulation of a-SMA mRNA and
reorganization of actin cytoskeleton in human lung fibroblast
(Evans et al., 2003). However, in vivo studies of mice showed
that the recruitment of inflammatory cells, including neu-
trophiles, mast cells, and myofibroblasts, in skin lesions after
irradiation is TGF-b1/activin/Smad3-dependent (Ashcroft
et al., 1999). Smad3 also has an important function in the
upregulation of TGF-b1 at the site of injury. Loss of Smad3 in
wild-type skin and Smad3-null skin shows reduction in
scarring (Flanders et al., 2003). Furthermore, overexpression
of Smad3 markedly increases a-SMA protein expression (Hu
et al., 2003). It appears that there is enough evidence to
suggest that inhibition of Smad3 and not Smad2 is the key
mediator of pathogenic effects of TGF-b1 in fibrosis. Our
study also suggests that TNF-a decreases a-SMA expression
via inhibition of Smad3 phosphorylation.
Several studies have demonstrated that TGF-b1 increases
tensile strength during wound healing (Mustoe et al., 1987;
Connors et al., 2000; Korenkov et al., 2005). For example,
Mustoe et al. (1987) found that TGF-b1 improved both the
breaking strength and the rate of healing in rats’ incisional
wounds. In contrast, exogenous administration of TNF-a has
been shown to both enhance and attenuate local collagen
synthesis and wound-breaking strength of cutaneous wounds
in mice and rats (Salomon et al., 1991; Maish et al., 1998;
Lee et al., 2000). Unfortunately, these studies have all been
performed in animals or using non-human tissues. Our study
used the stressed FPCL model to examine the interaction of
these mediators, as it probably occurs in the local tissue
microenvironment. Further, it is among the few attempts to
correlate the molecular response with mechanical behavior
induced by fibroblasts. In our project, we measured two
mechanical parameters of collagen lattice: contraction rate
and stiffness of the matrix. Our mechanical data correlate
with the molecular data in that increasing a-SMA, collagen
1A, and fibronectin mRNA levels under TGF-b1 stimulation
resulted in increasing stiffness and contraction of the matrix.
Conversely, stress FPCL treated with TNF-a together with
TGF-b1 had lower mRNA levels of a-SMA, collagen 1A, and
fibronectin. As expected, these FPCL matrices demonstrated
negligible contraction as well as lower tensile strength
compared with TGF-b1 treatment groups. It is of interest that
we found the same contraction response using the Bell free-
floating lattice contraction assay (Ehrlich and Rittenberg,
2000), in which TNF-a significantly reduced contraction
forces induced by TGF-b1 (data not shown). TNF-a can
reverse the stimulation of TGF-b1-induced collagen lattice
contraction in stressed as well as free-floating collagen
lattice.
We further correlated the rate of contraction with the
stiffness of the gels by plotting the Young’s modulus obtained
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from the indentation assay against the final area of contrac-
tion (Figure 9). Two main results are evident: (i) with the TGF-
b treatments, the stiffness increased along with the degree of
contraction (i.e., a lower final area) as compared with the
untreated control and (ii) in contrast, with the TNF-a
treatment, the stiffness decreased along the degree of
contraction as compared with the control. These results
suggest that the contraction and stiffness are coupled.
Namely, as contraction proceeds, there is a consequent
increase in stiffness, roughly corresponding to an increasing
density of the collagen matrix. In other words, the observed
increase/decrease in stiffness is the result of a greater/lesser
degree of contraction. Furthermore, we found that TGF-b1
induced marked alternation in the cell phenotype and
reorganization of the actin cytoskeleton, as demonstrated in
our rhodamine phalloidin staining. Larger organized stress
fibers in fibroblasts within stressed FPCL treated with TGF-b1
directly correlates with a greater degree of contraction as well
as an increase in matrix stiffness. Conversely, TNF-a
combined with TGF-b1 treatments resulted in a decreased
assembly of stress fibers, which correlates with reduction in
stiffness and contraction of collagen matrix. Recent work by
Goffin et al. (2006) demonstrated a-SMA as a mechano-
sensitive protein that is recruited to stress fibers under high
tension. They illustrated this phenomenon by growing
primary rat lung myofibroblasts on micro-pattern silicone
substrates of a given thickness (80 mm) and varying stiffnesses,
ranging from normal soft tissue to plastic. They demonstrated
that a-SMA recruitment to stress fibers of cultured myofibro-
blasts requires a substrate stiffness of approximately 16 kPa.
This is significantly different from the findings in our study, in
which a-SMA differentiation occurred in matrices with
stiffnesses of 1,700–2,200 Pa. There are many factors that
would contribute to the differences in our results. First, we
use primary human dermal fibroblasts embedded in three-
dimensional collagen 1 matrices, as opposed to rat lung
myofibroblasts grown on top of micro-pattern silicone
substrates. Second, we stimulated our human dermal
fibroblasts with TGF-b1 and showed myofibroblast differ-
entiation. We then measured the matrix stiffness. In our
experiments, we did not examine the redistribution of a-SMA
to stress fibers. Lastly, the substrates’ elastic moduli in the
work by Goffin et al. (2006) are the result of microscopic
measurements, whereas ours are macroscopic measurements
of normal soft tissue. The stiffness of matrices in our
experiments exhibited elastic moduli of 1,700–2,200 Pa,
which is consistent with recently published results from
Clark et al. (Ghosh et al., 2007). Clark et al. showed that adult
human dermal fibroblasts grown on hydrogels with a stiffness
of 4,270 Pa exhibited linear, stretched arrays of F-actin
microfilaments with uniform diameter similar to that of our
fibroblasts treated with TGF-b1. Our substrate stiffness is also
similar to the elastic modulus of normal soft tissue, 1–20 kPa
(Bao and Suresh, 2003).
In view of our results, we propose a functional relationship
between mechanics and molecular influences of TGF-b1 and
TNF-a on ECM reorganization in human dermal fibroblasts as
follows: TNF-a mediates its antagonistic effects on TGF-b1
through the JNK pathway. Inhibition of Smad3 phosphoryla-
tion leads to a decrease in transcription of TGF-b1 response
genes, that is, collagen 1A, fibronectin, and a-SMA. As a
consequence of these molecular changes, TNF-a suppresses
TGF-b1-induced myofibroblast differentiation and cytoskele-
tal changes necessary for efficient matrix contraction coupled
with matrix tensile strength. The model is summarized in
Figure 10.
The data in this paper could support a molecular and
mechanical mechanism for inflammation-induced abnormal
wound healing. Normally, TNF-a is not present during the re-
epithelialization and ECM reorganization phases of wound
healing (Singer and Clark, 1999). Normal cutaneous wound
healing is a coordinated sequence of events involving
clotting, inflammation, remodeling, and re-epithelization. In
the inflammation phase, infiltrating inflammatory cells
secrete growth factors (i.e., platelet-derived growth factor
and TGF-b) and cytokines (TNF-a) essential for cleansing the
wounded area of foreign particles and bacteria and initiating
myofibroblast-dependent wound contraction (Singer and
Clark, 1999). Healing proceeds only after the inflammation
has subsided. Under pathologic conditions, such as in
chronic wounds, the cascade of wound healing is disrupted
and the wounds are locked into a state of inflammation
characterized by abundant neutrophil infiltration with asso-
ciated reactive oxygen species and inflammatory cytokines
(TNF-a). Stacey et al. found very high level of TNF-a and low
levels of TGF-b1 in chronic wounds fluid compared to
healing wounds (Trengove et al., 2000). The results from our
study showed high levels of TNF-a in suppression of TGF-b1-
stimulated a-SMA, collagen, and fibrin synthesis. TNF-a-
suppressed myofibroblast differentiation and cytoskeletal
changes required for normal matrix contraction. Therefore,
chronic wounds with a high level of TNF-a would fail to
contract in a normal fashion. The granulation tissues in
chronic wounds are often characterized as fragile. We
have demonstrated here that matrices treated with TNF-a
TGF-1
TNF- Changes in collagen fibronectin synthesis 
inhibit myofibroblast differentiation 
resulting in changes in ECM quality
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Figure 10. A proposed mechanism of TNF-a suppression of TGF-b1-induced
gene expression. TNF-a inhibits TGF-b1-induced collagen 1a, fibronectin,
and a-SMA expression by inhibiting Smad3 phosphorylation via JNK
pathway. Inhibition of Smad3 phosphorylation precluded formation of
Smad3 and -4 complex and thus prevented it from regulating the target
gene. The overall effect of TNF-a is inhibition of TGF-b1-induced
myofibroblast differentiation, leading to softer and less contracted matrix.
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(10 ng/ml) have lower tensile strength than normal untreated
matrices. Continued inflammation, mediated by TNF-a,
might prevent normal matrix deposition and myofibroblast-
dependent wound contraction mediated by TGF-b1 in
normal wound healing.
MATERIALS AND METHODS
Reagents
Monoclonal Anti-a-SMA was purchased from Sigma (St Louis, MO).
Mouse monoclonal anti-a-SMA conjugated with FITC was purchased
from Sigma. Mouse anti-vimentin monoclonal antibody was
purchased from Chemicon International (Temecula, CA). Mouse
monoclonal anti-phospho-SAPK/JNK (Thr183/Tyr185) (G9), rabbit
polyclonal anti-phospho Smad3, and-rabbit polyclonal anti-JNK
were purchased from Cell Signaling Technology (Beverly, MA).
Recombinant human TNF-a and TGF-b1 were purchased from R&D
Systems (Minneapolis, MN). Purified collagen (Vitrogen 100) was
purchased from Cohesion Technology (Palo Alto, CA). Both selective
inhibitor SB202190 and SP600125 were purchased from Sigma.
Cell Cultures
Normal human dermal fibroblasts were obtained from adult human
skin discarded after reconstructive surgery. All experiments involving
human tissue were approved by the Institutional Review Board and
adhered to the Declaration of Helsinki Principles. Patient consents
were obtained as outlined in the USC IRB no.999061. Early passage
cells (passages 2–4) were used in all experiments. The isolated
fibroblasts were cultured in DMEM containing 10% FBS with
antibiotics (Gibco, Carlsbad, CA). Cells were cultured until they
were confluent. FPCLs were prepared at a final cell density of
300,000 cells/cm3 with a collagen concentration of 1 mg/ml. A drop
of 250 ml of cell/gel suspension was placed onto a 24-well tissue
culture plate, which remained attached throughout the culture
period. After polymerization for 1 hour at 371C, the stressed FPCL
was treated with TGF-b1 (1 ng/ml), TNF-a (1 ng/ml), or combinations
of TGF-b1 (1 ng/ml) and TNF-a (1 and 2 ng/ml) in 1.5 ml of DMEM
containing 0.1% FBS. This cell culture condition was used in our
Western blot and immunohistochemistry staining analysis.
Contraction assay
Human dermal fibroblasts were embedded in type I collagen at the
final concentration of 5 105 cells and collagen concentration of
1.5 mg/ml. A volume of 600ml per gel was fabricated in a 24-well
plastic culture dish, which ensured that the gel would remain
attached throughout the culture period. The cells were cultured in
10% FBS for 20 hours after polymerization. After 20 hours of
recovery in 10% FBS, the stressed FPCLs were incubated in 0.5%
FBS with TGF-b1 (1 ng/ml), TNF-a (1 ng/ml), and a combination of
TGF-b1 (1 ng/ml) and TNF-a (1 ng/ml). After 4 days in culture, the
stressed FPCLs were mechanically released from the plate and rapid
contraction was recorded in 1 hour.
Western blot
The stressed FPCLs were induced with different cytokines for
96 hours. Cell extracts were prepared with SDS sample buffer and
boiled for 3 minutes at 951C. Equal amounts of cell lysates were
separated on 12% SDS-PAGE gel. After electrophoresis, the
separated proteins were transferred to a nitrocellulose membrane.
The membrane was blocked with Tris-buffered saline (50 mM Tris,
pH 7.5, and 100 mM NaCl) containing 5% non-fat milk for 1 hour
and then incubated with the primary antibody at 41C overnight. The
blots were subsequently washed with Tris-buffered saline–Tween-20
(0.1%) and then incubated with an appropriate horseradish
peroxidase-conjugated secondary antibody from Pierce Biotechnol-
ogy (Rockford, IL) in saline-Tween. Proteins were visualized using
Femto-enhanced chemiluminescence according to the manufac-
turer’s instructions.
Immunohistochemistry staining
To analyze the effects of TGF-b1 and TNF-a on a-SMA protein
expression, human dermal fibroblasts (100,000 cells) were grown in
collagen I lattice (1 mg/ml). The stressed lattices were stimulated
with designated cytokines for 96 hours and then fixed with methanol
and treated with Triton-100 (0.15%). After blocking with 5% BSA,
the lattice was incubated with mouse monoclonal anti-a-SMA FITC
conjugate (1:200 dilution). The nucleus was counter stained with
propidium iodine.
The procedure for staining cells with rhodamine-conjugated
phalloidin is as follows: after 96 hours of stimulation with different
treatment conditions, the stressed FPCLs were fixed with 35%
methanol for 10 minutes followed by TritonX100 (0.12%) for
10 minutes. Phalloidin-cy3 (Sigma) at 20 mg/ml was used for staining
in phosphate-buffered saline overnight. The FPCLs were then
washed with phosphate-buffered saline and the nuclei were
counterstained with 40,6-diamidino-2-phenylindole at 1 mg/ml for
10 minutes. The stained FPCLs were visualized under the micro-
scope with an attached digital camera (Nikon, AG Heinze Precision
Microoptics, Chandler, AZ).
Measurement of a-SMA mRNA message stability
Normal human fibroblasts were grown to confluence in 10 cm2
plates in DMEM with 10% FBS. Confluent fibroblasts were serum-
starved in DMEM containing 0.1% FBS for 16 hours, followed by
induction with TGF-b1 (1 ng/ml) or TGF-b1 (1 ng/ml) combined with
TNF-a (1 ng/ml) for 24 hours. At the end of 24 hours of cytokine
stimulation, actinomycin D (2.5 mg/ml) was added and cells were
scraped at the indicated time points. Total RNA was extracted, and
real-time PCR was performed for a-SMA and GAPDH. t1/2 was
calculated as the amount of time required for the a-SMA message to
decrease 50% from initiation.
Total RNA extraction and cDNA synthesis
RNA was extracted from cells grown in stressed collagen type I
(1 mg/ml) lattices using Trizol (Life Technologies, Carlsbad, CA)
according to the manufacturer’s instructions. RNA was quantified
spectrometrically. Starting from 2mg RNA, 20 ml cDNA was
synthesized using random primers and SuperScript III Platinum as
well as a CellsDirect two-step quantitative reverse transcriptase PCR
kit from Invitrogen (Carlsbad, CA).
Real-time PCR
The cDNA samples were diluted 20 times. Five microliters of each
sample was used to measure mRNA levels of a-SMA, collagen 1,
fibronectin, and glyceraldehyde-3-phosphate dehydrogenase-
GAPDH using the qPCR Mastermix Plus for SYBR Green from
VWR. Reactions were performed and monitored using the ABI Prism
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7700 Sequence Detection System (Perkin Elmer, Waltham, MA). The
following primers were used: a-SMA: 50-CCGACCGAATGCAGAAG
GA-30, sense and 50-ACAGAGTATTTGCGCTCCGAA-30, antisense
(Knerr et al., 2001); collagen I: 50-CAGCCGCTTCACCTACAGC-30,
sense and 50-TTTTGTATTCAATCACTGTCTTGCC-30, antisense
(Frank et al., 2002); fibronectin: 50-GGAGAATTCAAGTGTGACCCT
CA-30, sense and 50-TGCCACTGTTCTCCTACGTGG-30, antisense
(Eikmans et al., 2003); GAPDH: 50-GAAGGTGAAGGTCGGAGT-30,
sense and 50-GAAGATGGTGATGGGATTTC-30, antisense. Expres-
sion levels for each gene of interest were calculated by normalizing
the quantified mRNA amount to the GAPDH mRNA. Each sample
was assessed in triplicate.
Compressive indentation mechanical assay
FPCLs, 1.0 ml (by vol), were prepared to the final cell concentration
of 300,000 plus collagen concentration of 1.5 mg/ml within standard
24-well culture plates. The gels remain attached to the dish
throughout the testing period. We characterized the mechanical
performance of the attached FPCL using an established compressive
indentation experimental protocol (Mooney et al., 2006). Specifi-
cally, after removal of the excess phosphate-buffered saline solution
from each well, a 3.0 mm circular, flat-ended glass punch was
pressed into the surfaces of the FPCLs at a controlled displacement
rate of 10 mm/minute to a final displacement, u, of 3 mm using an
Instron 3365 Universal Testing machine equipped with a 2.5 N load
cell. The force, F, and displacement, u, data were recorded and
analyzed to determine the Young’s modulus, a key elastic coefficient
of the FPCL governing its stiffness. This was done by fitting a linear
equation to the data between 0.0 and 0.5 mm and analyzing the
slope of the line in accordance with the Boussinesq elastic solution
for the flat punch indentation geometry:
F ¼ 2aE

1 u2
 
u
where a is the punch radius (1.5 mm), v is the Poisson’s ratio of the
FPCL, and F and u are the applied force and displacement,
respectively (Figure 2a–d). A Poisson’s ratio of 0.25 was assumed
for the FPCL. The experimental force–displacement data were
analyzed to yield the Young’s modulus (SI unit is Pa) of the FPCL
as a function of experimental condition. All experiments were
carried out in triplicate and data points and error bars in the figure
represent averages and standard deviations.
Statistical analysis
All values are presented as mean7SD Statistical analysis of
differences between triplicate sets of experiments were assessed
using a Student’s t-test, assuming double-sided independent variance
with Po0.05 considered significant.
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